Evidence map›Paper›PMID 40897924›Full record

ArticleDiabetologia2026

Improved wound healing by dual inhibition of miR-146a-5p and miR-29a-3p supports a network action of dysregulated miRNAs in diabetic skin.

Marija Petkovic, Ermelindo C Leal, Anja E Sørensen, Per T Jørgensen, Jesper T Wengel, Rosa R Jersie-Christensen, Jesper T Troelsen, Eugenia Carvalho, Louise T Dalgaard

Abstract read
In one paragraph

Article in Diabetologia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Marija PetkovicSteno Diabetes Center Copenhagen, Herlev Hospital, Herlev, Denmark.ORCID 0000-0003-0404-5241
Ermelindo C LealCNC-UC - Center for Neuroscience and Cell Biology, CIBB - Centre for Innovative Biomedicine and Biotechnology, University of Coimbra, Coimbra, Portugal.ORCID 0000-0003-1748-9861
Anja E SørensenDepartment of Science and Environment, Roskilde University, Roskilde, Denmark.ORCID 0000-0001-7557-5376
Per T JørgensenDepartment of Physics, Chemistry and Pharmacy, University of Southern Denmark, Odense, Denmark.ORCID 0000-0003-3932-5921
Jesper T WengelDepartment of Physics, Chemistry and Pharmacy, University of Southern Denmark, Odense, Denmark.ORCID 0000-0001-9835-1009
Rosa R Jersie-ChristensenDepartment of Science and Environment, Roskilde University, Roskilde, Denmark.ORCID 0000-0003-4706-5322
Jesper T TroelsenDepartment of Science and Environment, Roskilde University, Roskilde, Denmark.ORCID 0000-0002-4177-3267
Eugenia CarvalhoCNC-UC - Center for Neuroscience and Cell Biology, CIBB - Centre for Innovative Biomedicine and Biotechnology, University of Coimbra, Coimbra, Portugal. ecarvalh@cnc.uc.pt.ORCID 0000-0001-6264-3632
Louise T DalgaardDepartment of Science and Environment, Roskilde University, Roskilde, Denmark. ltd@ruc.dk.ORCID 0000-0002-3598-2775

Funding

RESOURCE CORE 3: ANALYTICAL COREP30AG028718 · NIA · UNIV OF ARKANSAS FOR MED SCIS · PI WEI, JEANNE Y · 2011 to 2015
$5.1M
STUDIES IN MATHEMATICS AND STATISTICSZ01CT000024 · CIT · COMPUTER RESEARCH AND TECHNOLOGY · PI WEISS, GEORGE H · 1985 to 2008
$408k
European Foundation for the Study of Diabetes Research Program in Microvascular ComplicationsEuropean Regional Development Fund Healthy Aging 2020-CENTRO-01-0145-FEDER-000012-N23Fundação para a Ciência e a Tecnologia DL57/2016/CP1448/CT0024Fundação para a Ciência e a Tecnologia LA/P/0058/2020Fundação para a Ciência e a Tecnologia POCI-01-0145-FEDER-007440Fundação para a Ciência e a Tecnologia UIDB/04539/2020Fundação para a Ciência e a Tecnologia UIDP/04539/2020Intramural NIH HHS Z01 CT000024NIA NIH HHS 5P30-AG028718NIA NIH HHS P30 AG028718Novo Nordisk Fonden NNF17SA0031406Novo Nordisk Fonden NNF22SA0079901Novo Nordisk Fonden NNF23OC0081177Novo Nordisk Fonden NNF24OC0089436
6 · The paper itself

Abstract

aims/hypothesisUpregulation of miR-146a-5p and miR-29-3p is observed in chronic non-healing wounds in diabetes. Their single or combined inhibition's molecular and cellular effects were assessed in human keratinocytes (HaCaT cells) and in vivo using a mouse model of type 1 diabetes.

methodsAs primary outcomes, we screened for proteome changes in HaCaT cells by LC-MS/MS after transfection with miR-146a-5p or miR-29a-3p inhibitors individually or in combination and following stimulation with TNF-α. Moreover, as a secondary outcome, we collected the data and cryopreserved and paraffin-embedded skin biopsies to estimate the tissue response to miRNA inhibition using immunofluorescence and histological analysis. Cryopreserved biopsies were also used for the LC-MS/MS proteome profiling to identify targets and cellular pathways involved in observed tissue changes.

resultsWe identified a panel of extracellular matrix proteins, mainly laminins, whose levels changed after transfection with miR-146a-5p or miR-29a-3p inhibitors in HaCaT cells, counteracting TNF-α effects. There was a difference in wound closure rate in vivo between the dual inhibition of miR-146a-5p and miR-29a-3p and scramble controls on day 8 (p<0.01) and day 9 (p<0.05), although not at day 10. Histological analysis at day 10 shows a loose papillary layer in the scramble inhibition group, indicating incomplete wound closure compared with dual miRNA inhibition. Moreover, the dual action of the inhibitors decreased inflammation at day 3 and day 10 (both p<0.001) and reactive oxygen species formation (p<0.01) 3 days post wounding, while increasing the angiogenesis on day 3 (p<0.01) and day 10 (p<0.001). This was consistent with cytoskeletal rearrangements and collagen alterations observed in proteome profiling. CONCLUSIONS/

interpretationThese findings demonstrate that dual inhibition of miR-146a-5p and miR-29a-3p in vitro synergises in a bidirectional manner, resulting either in intermediate effects or in cancelling each other's activity for the levels of specific proteins of basal lamina that impair proliferation and cell motility, compared with the individual inhibitors. Topical supplementation of miR-146a-5p and miR-29a-3p inhibitors to diabetic mouse wounds resulted in a reduction in wound size on days 8 and 9, which correspond to the later stages of healing, but did not lead to complete healing by day 10. However, dual inhibition demonstrates favourable effects on high oxidative stress, elevated inflammation and poor angiogenesis. These effects are superior to single miRNA inhibition, suggesting that combined miRNA inhibition could be a promising therapeutic strategy for diabetic wound healing. Nevertheless, further studies in humans are warranted.

Indexed as

Diabetes Mellitus, Type 1MicroRNAsSkinWound HealingAnimalsHaCaT CellsHumansKeratinocytesMaleMiceTumor Necrosis Factor-alphaMicroRNAsMIRN146 microRNA, humanMIRN29a microRNA, humanMIRN29 microRNA, mouseTumor Necrosis Factor-alphaAngiogenesisCollagenDiabetic wound healingExtracellular matrixInflammationLamininsmiRNANon-coding RNAReactive oxygen species

Identifiers

PMID40897924
PMCPMC12685990

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.